EUVIMEDEUVIMED entdecken
Open Access

Strategies to boost statistical efficiency in randomized oncology trials with primary time-to-event endpoints

Alan D Hutson iD, Han Yu iD

Statistical Methods in Medical Research · 2025

DOI: 10.1177/09622802251343599 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Statistical Methods in Medical Research, 2025. Verfasst von Alan D Hutson und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biostatistics and Bioinformatics, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA. Hauptthemen laut MEDLINE: Randomized Controlled Trials as Topic, Endpoint Determination, Medical Oncology. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, National Institutes of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Oncology clinical trials are increasingly expensive, necessitating efforts to streamline phase II and III trials to reduce costs and expedite treatment delivery. Randomization is often impractical in oncology trials due to small sample sizes and limited statistical power, leading to biased inferences. The FDA has recently published guidance documents encouraging the use of prognostic baseline measures to improve the precision of inferences around treatment effects. To address this, we propose an extension of Rosenbaum’s exact testing method incorporating a variant of martingale residuals for right censored data. This method can dramatically improve the statistical power of the test comparing treatment arms given time-to-event endpoints as compared to the standard log-rank test. Additionally, the modification of the martingale residual provides a straightforward metric for summarizing treatment effect by quantifying the expected events per treatment arm at each time-point. This approach is illustrated using a phase II clinical trial in small cell lung cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Randomized Controlled Trials as TopicEndpoint DeterminationMedical OncologyHumansClinical Trials, Phase II as TopicLung NeoplasmsModels, StatisticalSmall Cell Lung CarcinomaSample SizeData Interpretation, Statistical

Stichwörter der Autor:innen

Real world dataminimizationpermutation testrandomization test

Autor:innen und Institutionen

  • Department of Biostatistics and Bioinformatics, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.

ORCID-Profile: Alan D Hutson, Han Yu

Förderung

  • NCI NIH HHS
  • National Institutes of Health

Zitieren

APA

Hutson, A. D., & Yu, H. (2025). Strategies to boost statistical efficiency in randomized oncology trials with primary time-to-event endpoints. Statistical Methods in Medical Research. https://doi.org/10.1177/09622802251343599

Vancouver

Hutson AD, Yu H. Strategies to boost statistical efficiency in randomized oncology trials with primary time-to-event endpoints. Statistical Methods in Medical Research. 2025. doi:10.1177/09622802251343599

BibTeX
@article{Hutson2025,
  author = {Hutson, Alan D and Yu, Han},
  title = {Strategies to boost statistical efficiency in randomized oncology trials with primary time-to-event endpoints},
  journal = {Statistical Methods in Medical Research},
  year = {2025},
  doi = {10.1177/09622802251343599}
}
Kostenlos starten →